Class summary at a glance.

Every drug in the Estrogen Agonist/Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $77.6Mcombined across class
Total Rx claims: 1.7M517K unique beneficiaries
Generic mfrs (active): 19across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Raloxifene

Brand: Evista · 1.1M Part D claims (CY24) · 322K beneficiaries · First FDA approval: 1998-01-06

8 generic mfrs 0 plans require PA

Low NADAC$0.248

→

Avg plan cost$0.483

Part D spend $48.7M 2× spread, current vs floor

Class share

63%

of class CY24 spend

View profile →

Tamoxifen

Brand: SOLTAMOX · 577K Part D claims (CY24) · 185K beneficiaries · First FDA approval: 2003-02-20

5 generic mfrs 49 plans require PA

Low NADAC$0.139

→

Avg plan cost$0.515

Part D spend $16.0M 4× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Ospemifene

Brand: Osphena · 25K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 2023-04-01

Brand-only (no generics) 38 plans require PA

Low NADAC$8.16

→

Avg plan cost$8.16

Part D spend $11.4M 1× spread, current vs floor

Class share

15%

of class CY24 spend

View profile →

Clomiphene

Brand: CLOMID · 7K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2022-09-09

6 generic mfrs

Low NADAC$6.64

→

Avg plan cost$7.40

Part D spend $1.4M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.